122 related articles for article (PubMed ID: 2532072)
1. Effect of dipyridamole on fluorodeoxyuridine cytotoxicity in vitro and in cancer patients.
Buzaid AC; Alberts DS; Einspahr J; Mosley K; Peng YM; Tutsch K; Spears CP; Garewal HS
Cancer Chemother Pharmacol; 1989; 25(2):124-30. PubMed ID: 2532072
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of fluorinated pyrimidine-induced cytotoxicity by leucovorin in human lung cancer cell lines.
Tsai CM; Gazdar AF; Allegra C; Perng RP; Kramer BS
Int J Cancer; 1990 Jul; 46(1):101-5. PubMed ID: 2163987
[TBL] [Abstract][Full Text] [Related]
3. Modulation of RTX cytotoxicity by thymidine and dipyridamole in vitro: implications for chemotherapy.
Lehman NL; Danenberg PV
Cancer Chemother Pharmacol; 2000; 45(2):142-8. PubMed ID: 10663629
[TBL] [Abstract][Full Text] [Related]
4. Antiproliferative effect of immunoliposomes containing 5-fluorodeoxyuridine-dipalmitate on colon cancer cells.
Koning GA; Gorter A; Scherphof GL; Kamps JA
Br J Cancer; 1999 Aug; 80(11):1718-25. PubMed ID: 10468287
[TBL] [Abstract][Full Text] [Related]
5. Pharmacologic basis for the use of dipyridamole to increase the selectivity of intraperitoneally delivered methotrexate.
Goel R; Sanga R; Howell SB
Cancer Chemother Pharmacol; 1989; 25(3):167-72. PubMed ID: 2598406
[TBL] [Abstract][Full Text] [Related]
6. Fluorodeoxyuridine with continuous leucovorin infusion. A phase II clinical trial in patients with metastatic colorectal cancer.
Levin RD; Gordon JH
Cancer; 1993 Nov; 72(10):2895-901. PubMed ID: 8221555
[TBL] [Abstract][Full Text] [Related]
7. Effects of FUdR on primary-cultured colon carcinomas metastatic to the liver.
Schroy PC; Cohen A; Winawer SJ; Friedman EA
J Surg Oncol; 1990 Dec; 45(4):217-23. PubMed ID: 2147452
[TBL] [Abstract][Full Text] [Related]
8. A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer.
Kemeny N; Seiter K; Niedzwiecki D; Chapman D; Sigurdson E; Cohen A; Botet J; Oderman P; Murray P
Cancer; 1992 Jan; 69(2):327-34. PubMed ID: 1303612
[TBL] [Abstract][Full Text] [Related]
9. The therapeutic impact of dipyridamole: chemopotentiation of the cytotoxic combination 5-fluorouracil/cisplatin in an animal model of human bladder cancer.
Keane TE; Rosner GL; Gingrich JR; Poulton SH; Walther PJ
J Urol; 1991 Nov; 146(5):1418-24. PubMed ID: 1942313
[TBL] [Abstract][Full Text] [Related]
10. Efficient intracellular delivery of 5-fluorodeoxyuridine into colon cancer cells by targeted immunoliposomes.
Koning GA; Kamps JA; Scherphof GL
Cancer Detect Prev; 2002; 26(4):299-307. PubMed ID: 12430634
[TBL] [Abstract][Full Text] [Related]
11. Augmentation of 5-fluorouracil cytotoxicity in human colon cancer cells by dipyridamole.
Grem JL; Fischer PH
Cancer Res; 1985 Jul; 45(7):2967-72. PubMed ID: 4005834
[TBL] [Abstract][Full Text] [Related]
12. Failure of orally administered dipyridamole to enhance the antineoplastic activity of fluorouracil in combination with leucovorin in patients with advanced colorectal cancer: a prospective randomized trial.
Köhne CH; Hiddemann W; Schüller J; Weiss J; Lohrmann HP; Schmitz-Hübner U; Bodenstein H; Schöber C; Wilke H; Grem J
J Clin Oncol; 1995 May; 13(5):1201-8. PubMed ID: 7738622
[TBL] [Abstract][Full Text] [Related]
13. A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial.
Hohn DC; Stagg RJ; Friedman MA; Hannigan JF; Rayner A; Ignoffo RJ; Acord P; Lewis BJ
J Clin Oncol; 1989 Nov; 7(11):1646-54. PubMed ID: 2530317
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of 5-fluorouracil's anticancer activity by dipyridamole.
Grem JL; Fischer PH
Pharmacol Ther; 1989; 40(3):349-71. PubMed ID: 2646650
[TBL] [Abstract][Full Text] [Related]
15. 5-Fluorouracil's cytotoxicity is enhanced both in vitro and in vivo by concomitant treatment with hyperthermia and dipyridamole.
Maehara Y; Sakaguchi Y; Takahashi I; Yoshida M; Kusumoto H; Masuda H; Sugimachi K
Cancer Chemother Pharmacol; 1992; 29(4):257-60. PubMed ID: 1537070
[TBL] [Abstract][Full Text] [Related]
16. The effect of liver macrophages on in vitro cytolytic activity of 5FU and FUdR on colon carcinoma cells: evidence of macrophage activation.
Daemen T; Regts J; Morselt H; Scherphof GL
Int J Immunopharmacol; 1992 Jul; 14(5):857-64. PubMed ID: 1387390
[TBL] [Abstract][Full Text] [Related]
17. Alternating hepatic intra-arterial floxuridine and fluorouracil: a less toxic regimen for treatment of liver metastases from colorectal cancer.
Stagg RJ; Venook AP; Chase JL; Lewis BJ; Warren RS; Roh M; Mulvihill SJ; Grobman BJ; Rayner AA; Hohn DC
J Natl Cancer Inst; 1991 Mar; 83(6):423-8. PubMed ID: 1825674
[TBL] [Abstract][Full Text] [Related]
18. Isolated lung perfusion with FUDR in the rat: pharmacokinetics and survival.
Port JL; Ng B; Ellis JL; Nawata S; Lenert JT; Burt ME
Ann Thorac Surg; 1996 Sep; 62(3):848-52. PubMed ID: 8784018
[TBL] [Abstract][Full Text] [Related]
19. Hepatic arterial floxuridine and leucovorin for unresectable liver metastases from colorectal carcinoma. New dose schedules and survival update.
Kemeny N; Seiter K; Conti JA; Cohen A; Bertino JR; Sigurdson ER; Botet J; Chapman D; Mazumdar M; Budd AJ
Cancer; 1994 Feb; 73(4):1134-42. PubMed ID: 8313315
[TBL] [Abstract][Full Text] [Related]
20. In vitro antitumor activity of 2'-deoxy-5-fluorouridine-monoclonal antibody conjugates.
Goerlach A; Krauer KG; McKenzie IF; Pietersz GA
Bioconjug Chem; 1991; 2(2):96-101. PubMed ID: 1831049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
